Sigea S.R.L.
Records under this name other than patents Sigea S.R.L. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,247,546 | Derivatives of acid polysaccharides Formerly held In force · USPTO record | In force | USPTO record | |
| US 8,324,356 | Polysaccharide derivatives of lipoic acid, and their preparation and use as skin cosmetics and medical devices Formerly held In force · USPTO record | In force | USPTO record | |
| US 8,530,450 | Mixed butyric-formic esters of acid polysaccharides, and their preparation and use as skin cosmetics Formerly held In force · USPTO record | In force | USPTO record | |
| US 9,649,269 | Use of glycosaminoglycan lipoate esters in the trichology field Formerly held In force · USPTO record | In force | USPTO record | |
| US 9,314,418 | Use of glycosaminoglycan lipoate esters in the trichology field Formerly held In force · USPTO record | In force | USPTO record | |
| US 10,618,982 | Process in water for the preparation of butyric esters of hyaluronic acid sodium salt Formerly held In force · USPTO record | In force | USPTO record | |
| US 8,629,252 | Polysaccharides derivatised with citric acid Lapsed on the fee record Ended Jan 14, 2026 · USPTO record | Lapsed on the fee record | Ended Jan 14, 2026 | USPTO record |
| US 6,140,313 | Butyric esters with antiproliferative activity and the pharmaceutical compositions containing them Term ended Term ended May 25, 2019 · USPTO record | Term ended | Term ended May 25, 2019 | USPTO record |
| US 7,169,948 | Anionic and neutral complexes of ruthenium (II) with nitrogen oxide Lapsed on the fee record Ended Jan 30, 2019 · USPTO record | Lapsed on the fee record | Ended Jan 30, 2019 | USPTO record |
| US 6,221,905 | Salts of anionic complexes of RU(III), as antimetastatic and antineoplastic agents Term ended Term ended Dec 30, 2018 · USPTO record | Term ended | Term ended Dec 30, 2018 | USPTO record |